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Abstract
Background: Many studies have reported several transcriptionally deregulated microRNAs (miRNAs) in papillary
thyroid cancer (PTC) tissue in comparison with benign thyroid nodules and normal thyroid tissues. However, the
correlation between miRNA expressions and PTC recurrence still remains unclear.
Methods: The PTC patients who scheduled to undergo total thyroidectomy by the same surgical team in Ningbo
NO.2 Hospital from March 1998 to March 2008 were enrolled in this study. The clinical and pathological
characteristics of each patient were recorded in detail. The selected miRNA expressions were detected using
quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). Potential predictive factors for cancer
recurrence were evaluated by univariate and multivariate Cox proportional hazard analysis.
Results: A total of 78 patients were enrolled with 49 females at a mean age of 45.8 years. Enrolled patients were
divided into two groups: nonrecurrent group (n = 54) and recurrent group (n = 24). The results from the univariate
Cox proportional hazard analysis revealed that primary tumor size, TNM stage, extrathyroid extension, miR-221, and
miR-222 expressions were significantly associated with PTC recurrence (P < 0.05). The tissue expression of miR-221
was the only independent risk factor for PTC recurrence (HR 1.41; 95%CI 1.14–1.95, P = 0.007) by multiple Cox
proportional hazard analysis.
Conclusions: This study identified the potential role of miR-221 as a prognostic biomarker for the recurrence in PTC.
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Background
Thyroid cancer is the most prevalent and rapidly
increasing endocrine neoplasm. The number of new
cases is almost 300,000 worldwide with a median age at
diagnosis of 50 years and nearly 40,000 deaths per year
[1]. The most common histological type of all thyroid
cancers is papillary thyroid cancer (PTC), which is
defined as a differentiated neoplasia and accounts for
approximately 80%. Most PTC patients are with good
prognosis, and the 10-year survival rate is about 90% [2].
However, the incidence of lymph node metastasis can be
as high as 20–50% [3], and PTC patients undergoing
total thyroidectomy are with a regional recurrence of
5–20% [4, 5]. Currently, needle aspiration biopsy is
the gold standard for diagnosis, but the predicative
value for recurrence is rather limited [6]. Risk factors
for the prognosis and recurrence of PTC are contro-
versial among different current guidelines [7, 8].
Therefore, investigating potential useful markers for
the identification and distinction of recurrence risk
factors is extremely imperative and necessary [9].
MicroRNAs (miRNAs), small noncoding single-stranded
RNAs, exert important actions in the development and me-
tastasis of cancer as reported by previous studies [10, 11].
Some miRNAs have already been suggested as potential
prognostic markers for the evaluation of cancer types,
stages, or progression [12, 13]. Recent studies have also
observed several transcriptionally deregulated miRNAs in
PTC tissue in comparison with benign thyroid nodules and
normal thyroid tissues [14, 15]. However, the correlation
between miRNA expressions and PTC recurrence still
remains unclear.
Previous studies have frequently reported that some
miRNAs including miR-21, miR-9, miR-10b, miR-146b,
miR-31, miR-220, miR-221, and miR-222 are abnormally
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expressed in thyroid cancers compared with healthy
controls [16–19]. In this present study, we investigate




This study protocol was approved by the Medical Insti-
tutional Ethics Committee of Zhejiang province. The
PTC patients who scheduled to undergo total thyroi-
dectomy by the same surgical team in Ningbo NO.2
Hospital from March 1998 to March 2008 were eligible
to enter this study. All patients included were required
to offer written informed consent. The formalin-fixed,
paraffin-embedded (FFPE) PTC tissues were procured
for the postoperative histopathologic diagnosis and
miRNA measurements. Those patients with poor quality
of tissues, missed follow-up data, or with no signed in-
formed consent were excluded from this study. A total
of 78 patients were enrolled with 49 females (62.8%) at
a mean age of 45.8 years. Enrolled patients were di-
vided into two groups: nonrecurrent group (n = 54)
and recurrent group (n = 24). Only those patients with
no recurrence after a 120-month follow-up evaluated
by clinical, laboratorial, and radiological evidence were
categorized in nonrecurrent group. Recurrence in this
present study was defined as locoregional recurrence
or distant metastasis. The median follow-up period
was 68 (range 8–158) months.
Methods
Selective neck dissections were performed in PTC
patients with regional lymph node metastases consider-
ing the metastases location. Our practice including the
radioactive iodine (RAI) and surgical management
evolved according to the latest American Thyroid Asso-
ciation (ATA) guidelines. All the patients were followed
up through outpatient department clinic regularly over
time. The conduction of postoperative RAI therapy was
under the direction of the ATA guidelines [7]. Two
independent pathologists blinded to this study were
required for the evaluation of tumor histopathologic
features. The ATA classification, risk stratification by
Memorial Sloan Kettering Cancer Center (MSKCC–NY)
[20], and stage by Union for International Cancer Control
(UICC) TNM [21] were also evaluated. The clinical and
pathological characteristics of each patient were recorded
in detail.
Tissue samples and RNA extraction
In this study, we use the areas containing over >90%
malignant tissue annotated by the same experienced
pathologist as the available PTC tissue samples. Man-
ual macrodissection was performed in archival FFPE
blocks for RNA extraction. Approximately 5–10-um-
thick sections from the FFPE PTC tissues were ob-
tained for total RNA extraction by utilizing RNeasy
Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. NanoDrop ND1000 Spe-
ctrophotometer (ThermoFisher Scientific, Waltham,
Mass) was used for the assessment of RNA quality
and concentration.
qRT-PCR for miRNA measurement
The miRNA expressions were detected using quantita-
tive reverse transcriptase-polymerase chain reaction
(qRT-PCR) with TaqMan miRNA assays (Applied Bio-
systems, Foster City, Calif ) and the △△Ct method. In
brief, TaqMan miRNA primers were used for the synthe-
sis of cDNA from total RNA, following the manufac-
turer’s instructions. The TaqMan miRNA probes and a
7500 Real-time PCR System were utilized for amplifica-
tion of PCR products. Two PCR reactions were per-
formed per sample following the manufacturer’s
protocol. RNU48 expression levels were used as an en-
dogenous control for data normalization [22]. As for
those cases of multifocal PTCs, the sample obtained
from available multifocal PTC tissues was all subjected
to miRNA qRT-PCR. The final data were described with
the mean value.
Statistical analysis
SPSS 21.0 (SPSS, Inc.) was utilized for data analysis in
this study. Data were presented as number (n) and
percentage (%), or mean ± standard error (SE) when
appropriate. We used chi-square or Fisher’s exact tests
to analyze clinical categorical data as appropriate.
Continuous data was analyzed by Student’s t tests or
Mann-Whitney U tests. Potential predictive factors for
cancer recurrence were evaluated by univariate and
multivariate Cox proportional hazard analysis, and
statistical difference was set as P < 0.05.
Results
Patient characteristics and PTC recurrence
A total of 78 eligible patients with a mean age of
45.8 years and mean tumor size of 24.5 (range 8–47)
mm were enrolled in this study with signed informed
consent. Fifty-four of all the included patients were
categorized into nonrecurrent group with a mean age of
44.9 years.
It has been observed that those patients with higher
ATA risks, higher MSKCC–NY risks, a larger primary
tumor size, or higher TNM stages were more likely to
result in the PTC recurrence (P < 0.05) (see Table 1).
Moreover, the patients in recurrent group were also with
a higher percentage of extrathyroid extension and cer-
vical lymph node metastasis (P < 0.05).
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Tissue miRNA expressions and PTC recurrence
To investigate the potential associations between tissue
miRNA expressions and PTC recurrence, we evaluated
miR-21, miR-9, miR-10b, miR-146b, miR-31, miR-220,
miR-221, and miR-222 by qRT-PCR. As shown in
Table 2, miR-146b, miR-220, miR-221, and miR-222
were markedly higher, while miR-9 and miR-21 expres-
sions were significantly lower in recurrent group when
compared with the nonrecurrent group (P < 0.05).
Univariate and multiple Cox proportional hazard analysis
for PTC recurrence
The univariate and multiple Cox proportional hazard
analysis was utilized for the investigation of potential
variables for predicating PTC recurrence. The all poten-
tial recurrence-associated variables including clinical,
pathological parameters, and tissue miRNA expressions
(Table 1 and Fig. 1) were involved into Cox proportional
hazard model. The results from univariate Cox propor-
tional hazard analysis revealed that primary tumor size,
TNM stage, extrathyroid extension, miR-221, and miR-
222 expressions were significantly associated PTC recur-
rence (P < 0.05). The tissue expression of miR-221 was
the only independent risk factor for PTC recurrence
(HR 1.41; 95%CI 1.14–1.95, P = 0.007) by multiple Cox
proportional hazard analysis (Table 3).
MiR-221 and other recurrence-associated parameters
No close association between miR-221 levels and time to
recurrence was found by linear analysis. As shown in
Table 3, the patients with higher miR-221 expressions
(>median level) were associated with higher thyroglobu-
lin levels. There was no significant association between
miR-221 levels with disease-free interval and cervical
lymph node metastasis rate.
Discussion
The valid predicative biomarkers for PTC recurrence
would help adequate assessment of PTC patients, less
Table 1 Characteristics of patients and PTC recurrence
Parameters Recurrent
group (n = 24)
Nonrecurrent
group (n = 54)
P value
Age (year) 44.9 ± 22.5 46.2 ± 18.9 0.792
Sex
Male 5(%) 13(%) 0.754
Female 19(%) 41(%)
ASA physical status
I 8(%) 20(%) 0.673
II 11(%) 27(%)
III 5(%) 7(%)
BMI (kg/m2) 21.4 ± 4.3 20.7 ± 3.8 0.473
ATA risk




Low 4 11 0.017*
Intermediate 10 36
High 10 7
Primary tumor size (mm) 29.4 ± 5.4 22.3 ± 4.8 <0.001*
Lymph node dissection 15(62.5%) 37(68.5%) 0.603
RAI postoperatively 6(25.0%) 22(40.7%) 0.181
Recurrence place
Locoregional 22(%) 47(%)
Distant metastasis 2(%) 7(%) 0.713
Serum thyroglobulin (ng/mL) 1.6 ± 1.4 1.0 ± 1.3 0.071
TNM stage
I–II 13 43 0.021*
III–IV 11 11
Extrathyroid extension
Yes 15 17 0.010*
No 9 37
Vascular invasion
Yes 11 18 0.292
No 13 36
Perineural invasion
Yes 6 7 0.188
No 18 47
Cervical lymph node metastasis
Yes 7 6 0.048*
No 17 48
Histological subtype
Classic 19 42 0.891
Follicular 5 12
Table 1 Characteristics of patients and PTC recurrence
(Continued)
Multifocal tumors
Yes 13 19 0.116
No 11 35
Bilateral tumors
Yes 7 16 0.967
No 17 38
P values were calculated by chi-square test, Fisher’s exact test, Student’s t test,
or Mann-Whitney U tests
PTC papillary thyroid cancer, ASA American Society of Anesthesiologists, BMI
body mass index, ATA American Thyroid Association, MSKCC–NY Memorial
Sloan Kettering Cancer Center
*P value <0.05
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prophylactic lymph node resections, or extensive surger-
ies. Whether prophylactic cervical lymph node dissec-
tion could improve postoperative survival or prevent
PTC recurrence still remains controversial [23, 24].
However, no such effective biomarkers have been found
until now, and great efforts are carried out by re-
searchers for this purpose. This present study aimed at
investigating potential biomarkers for PTC recurrence
including tissue miRNA expressions.
Previous studies have revealed that larger tumor size
was associated with increased incidence of nodal spread
and worse prognosis [25, 26]. Several reports have also
suggested tumor size as a predictor for central lymph
node metastases in PTC patients [27]. However, our final
Table 2 Univariate and multiple Cox proportional hazard analysis between clinical and pathological variables with PTC recurrence
Univariate Multivariate
Variables HR(95%CI) P value HR(95%CI) P value
ATA risk
Low × high 1.67(0.38–7.64) 0.389
Low × intermediate 0.87(0.29–3.35) 0.879
Intermediate × high 3.34(1.42–6.75) 0.087
MSKCC–NY risk
Low × high 1.67(0.77–3.98) 0.196
Low × intermediate 2.12(0.78–5.86) 0.132
Intermediate × high 1.45(0.52–3.88) 0.243
Primary tumor size 5.14(3.14–11.64) 0.009* 1.54(0.43–7.67) 0.567
TNM stage
I/II × III/IV 4.31(2.01–9.87) 0.011* 2.68(1.10–6.72) 0.067
Extrathyroid extension 2.12(0.78–6.81) 0.021* 2.53(0.54–12.42) 0.314





miR-221 1.46(1.20–1.88) 0.001* 1.41(1.14–1.95) 0.007*
miR-222 2.81(1.11–7.21) 0.021* 1.86(0.76–5.65) 0.226
PTC, papillary thyroid cancer, ATA American Thyroid Association, MSKCC–NY Memorial Sloan Kettering Cancer Center, CI confidence interval, HR hazard ratio
*P value <0.05
Fig. 1 Relative expressions of tissue microRNAs including miR-21 (a), miR-9 (b), miR-10b (c), miR-146b (d), miR-31 (e), miR-220 (f), miR-221 (g) and
miR-222 (h) in papillary thyroid cancer (PTC) patients with or without recurrence
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multiple Cox analysis did not support these factors as
predictive factors for PTC recurrence.
Previous studies have revealed the oncogenic and
tumor suppressor roles of miRNAs during the formation
and progression of tumors through the pathway modula-
tion. Furthermore, several miRNAs have been reported
closely correlated with the proliferation, progression,
metastasis, and invasion of tumors [12]. Some re-
searchers also suggest some miRNAs may exert predict-
ive roles in cancer [13]. However, whether tissue or
serum miRNAs could actually assist in the predication
of PTC recurrence is still unclear. In this study, we
examined a panel of tissue miRNA expressions to investi-
gate potential biomarkers for PTC recurrence by qRT-
PCR. The tissue expressions of miR-9, miR-21, miR-146b,
miR-220, miR-221, and miR-222 in recurrent group were
significantly different from the nonrecurrent group. The
downregulated miR-9 and miR-21 expressions in re-
current group comparing with nonrecurrent group were
in accordance with other studies [1]. MiR-146b is also
reported overexpressed in PTC tissues and closely as-
sociated with high-risk features including BRAF mutation
or extrathyroidal invasion [28]. Overexpressed miR-221
and miR-222 in PTC are closely correlated with clinic-
pathological characteristics and tumor aggression [15, 19].
As reported by previous studies, miR-220 was deregulated
in the PTC tissues vs. the normal tissues [14]. Our analysis
demonstrated that miR-220 expressions were significantly
higher in recurrent group compared with nonrecurrent
group. In this present study, we indicated miR-221 expres-
sions in PTC samples as potential biomarkers for PTC
recurrence. Excessively secreted miR-221 levels have been
observed in PTC, follicular, and anaplastic thyroid cancers
[29]. Previous studies also indicate that excessive expres-
sions of miR-221 act as an important role in the prolifera-
tion of thyroid cancer cells [14]. Sehu S et al. also report
the significantly different expressions of miR-221 between
benign follicular adenoma, multinodular goiter, and PTC
samples [30]. All these findings strongly suggest a close
correlation between miR-221 and PTC.
Some findings have revealed the crucial role of miR-221
in the occurrence or progression of human osteosarcoma
and suggested miR-221 as a promising marker for the
diagnostic and prognostic potentials for osteosarcoma
[31]. MiR-221 was also recommended as a significant
prognostic factor of clear cell renal cell carcinoma [32]. As
one of the most sensitive miRNAs for PTC [33], miR-221
was identified as a predictive biomarker for PTC recur-
rence in this study. Enhanced expression of miR-221 and
miR-222 plays a critical role in melanoma progression by
activating fundamental pathways, such as blocking mela-
nogenesis and inducing cell survival [34]. F. Acibucu et al.
indicate that upregulated miR-221 can promote breast
cancer progression by suppressing E-cadherin expression
[35]. MiR-221 is established as a tumor suppressor for
prostate cancer uniquely by targeting Runx2 [36]. These
may be possible molecular mechanisms of that miR-221
lead to increased cancer growth and progression.
Conclusions
In conclusion, this study identified miR-221 as a signifi-
cant independent predictor for PTC recurrence. However,
our study also had some limitations. First, a long-term
follow-up in the current study and larger cohorts are
required to support miR-221 as a useful biomarker for
PTC recurrence in clinical practice. Second, the ATA
guidelines changed throughout the collection period,
and our practice including the RAI and surgical manage-
ment evolved according to the latest ATA guidelines.
Whether the changed RAI and surgical management
would affect our results remained unclear. Third, the
involved mechanisms why miR-221 expression could
serve as potential predicative factor for recurrence in PTC
still remained unknown.
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Table 3 Relative miR-221 expressions and recurrence-associated
parameters
Relative expressions of miR-221
Parameters High (n = 12) Low (n = 12) P value
Disease-free interval (year) 1.8 ± 4.7 1.3 ± 5.3 0.801
Thyroglobulin (ng/mL) 1.5 ± 1.0 0.6 ± 0.9 0.031*
Cervical lymph node metastasis 5/12 2/12 0.371
P values were calculated by Mann-Whitney U tests or Fisher’s exact test
*P value <0.05
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